About: Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
Creator	Smith, R Chen, T Phillips, G Frankel, S Badros, A Chambers, S Cottler-Fox, M Fassas, A Fenton, R Heyman, M Hudes, R Jacobs, M Kennedy, A Kight, L Macfadden, M Meisenberg, B Mookerjee, B Rapoport, A Ruehle, K Sarkodee-Adoo, C Takebe, N Tricot, G
Source	PMC
abstract	Disease relapse occurs in 50% or more of patients who are autografted for relapsed or refractory lymphoma (NHL) or Hodgkin's disease (HD). The administration of non-cross-resistant therapies during the post-transplant phase could possibly control residual disease and delay or prevent its progression. To test this approach, 55 patients with relapsed/refractory or high-risk NHL or relapsed/refractory HD were enrolled in the following protocol: stem cell mobilization: cyclophosphamide (4.5 g/m(2)) + etoposide (2.0 g/m(2)) followed by GM-CSF or G-CSF; high-dose therapy: gemcitabine (1.0 g/m(2)) on day −5, BCNU (300 mg/m(2)) + gemcitabine (1.0 g/m(2)) on day −2, melphalan (140 mg/m(2)) on day −1, blood stem cell infusion on day 0; post-transplant immunotherapy (B cell NHL): rituxan (375 mg/m(2)) weekly for 4 weeks + GM-CSF (250 μg thrice weekly) (weeks 4–8); post-transplant involved-field radiotherapy (HD): 30–40 Gy to pre-transplant areas of disease (weeks 4–8); post-transplant consolidation chemotherapy (all patients): dexamethasone (40 mg daily)/cyclophosphamide (300 mg/m(2)/day)/etoposide (30 mg/m(2)/day)/cisplatin (15 mg/m(2)/day) by continuous intravenous infusion for 4 days + gemcitabine (1.0 g/m(2), day 3) (months 3 + 9) alternating with dexamethasone/paclitaxel (135 mg/m(2))/cisplatin (75 mg/m(2)) (months 6 + 12). Of the 33 patients with B cell lymphoma, 14 had primary refractory disease (42%), 12 had relapsed disease (36%) and seven had high-risk disease in first CR (21%). For the entire group, the 2-year Kaplan–Meier event-free survival (EFS) and overall survival (OS) were 30% and 35%, respectively, while six of 33 patients (18%) died before day 100 from transplant-related complications. The rituxan/GM-CSF phase was well-tolerated by the 26 patients who were treated and led to radiographic responses in seven patients; an eighth patient with a blastic variant of mantle-cell lymphoma had clearance of marrow involvement after rituxan/GM-CSF. Of the 22 patients with relapsed/refractory HD (21 patients) or high-risk T cell lymphoblastic lymphoma (one patient), the 2-year Kaplan–Meier EFS and OS were 70% and 85%, respectively, while two of 22 patients (9%) died before day 100 from transplant-related complications. Eight patients received involved field radiation and seven had radiographic responses within the treatment fields. A total of 72 courses of post-transplant consolidation chemotherapy were administered to 26 of the 55 total patients. Transient grade 3–4 myelosuppression was common and one patient died from neutropenic sepsis, but no patients required an infusion of backup stem cells. After adjustment for known prognostic factors, the EFS for the cohort of HD patients was significantly better than the EFS for an historical cohort of HD patients autografted after BEAC (BCNU/etoposide/cytarabine/cyclophosphamide) without consolidation chemotherapy (P = 0.015). In conclusion, post-transplant consolidation therapy is feasible and well-tolerated for patients autografted for aggressive NHL and HD and may be associated with improved progression-free survival particularly for patients with HD. Bone Marrow Transplantation (2002) 29, 303–312. doi:10.1038/sj.bmt.1703363
has issue date	2002-03-04(xsd:dateTime)
bibo:doi	10.1038/sj.bmt.1703363
bibo:pmid	11896427
has license	no-cc
sha1sum (hex)	e96a92420042a55c6681079ad5e5a7830a0f9031
schema:url	https://doi.org/10.1038/sj.bmt.1703363
resource representing a document's title	Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
has PubMed Central identifier	PMC7091694
has PubMed identifier	11896427
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:e96a92420042a55c6681079ad5e5a7830a0f9031#body_text
is schema:about of	named entity 'radiotherapy' named entity 'weeks' named entity 'BCNU' named entity 'cyclophosphamide' named entity 'cisplatin' named entity 'therapy' named entity 'control' named entity 'patients' named entity 'advanced' named entity 'Autotransplantation' named entity 'POSSIBLY' named entity 'REFRACTORY DISEASE' named entity 'G-CSF' covid:arg/e96a92420042a55c6681079ad5e5a7830a0f9031 named entity 'relapsed' named entity 'day' named entity 'disease' named entity 'lymphoma' named entity 'progression' named entity 'areas' named entity 'consolidation' named entity 'immunotherapy' named entity 'disease' named entity 'cisplatin' named entity 'refractory' named entity 'chemotherapy' named entity 'lymphoma' named entity 'Disease' named entity 'etoposide' named entity 'gemcitabine' named entity 'lymphoma' named entity 'rituxan' named entity 'refractory disease' named entity 'Hodgkin's disease' named entity 'cisplatin' named entity 'G-CSF' named entity 'etoposide' named entity '2.0' named entity 'B cell' named entity 'cisplatin' named entity 'lymphoma' named entity 'rituxan' named entity 'radiographic' named entity 'NHL' named entity 'LDH' named entity 'neutrophil' named entity 'hematopoietic growth factor' named entity 'restrictive lung disease' named entity 'adenopathy' named entity 'antibody' named entity 'cyclophosphamide' named entity 'infusion' named entity 'stem cell' named entity 'high-dose' named entity 'NHL' named entity 'lymphomas' named entity 'radiographic' named entity 'gemcitabine' named entity '95% CI' named entity 'gemcitabine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software